Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection

Alexander J. McAuley, Bevan Sawatsky, Thomas Ksiazek, Maricela Torres, Miša Korva, Stanka Lotrič-Furlan, Tatjana Avšič-Županc, Veronika Von Messling, Michael R. Holbrook, Alexander Freiberg, David Beasley, Dennis Bente

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The tick-borne encephalitis complex contains a number of flaviviruses that share close genetic homology, and are responsible for significant human morbidity and mortality with widespread geographical range. Although many members of this complex have been recognised for decades, licenced human vaccines with broad availability are only available for tick-borne encephalitis virus. While tick-borne encephalitis virus vaccines have been demonstrated to induce significant protective immunity, as determined by virus-neutralisation titres, vaccine breakthrough (clinical infection following complete vaccination), has been described. The aim of this study was to confirm the cross-neutralisation of tick-borne flaviviruses using mouse immune ascitic fluids, and to determine the magnitude of cross-neutralising antibody titres in sera from donors following tick-borne encephalitis vaccination, infection, and vaccine breakthrough. The results demonstrate that there is significant cross-neutralisation of representative members of the tick-borne encephalitis complex following vaccination and/or infection, and that the magnitude of immune responses varies based upon the exposure type. Donor sera successfully neutralised most of the viruses tested, with 85% of vaccinees neutralising Kyasanur forest disease virus and 73% of vaccinees neutralising Alkhumra virus. By contrast, only 63% of vaccinees neutralised Powassan virus, with none of these neutralisation titres exceeding 1:60. Taken together, the data suggest that tick-borne encephalitis virus vaccination may protect against most of the members of the tick-borne encephalitis complex including Kyasanur forest disease virus and Alkhumra virus, but that the neutralisation of Powassan virus following tick-borne encephalitis vaccination is minimal.

Original languageEnglish (US)
Article number9
Journalnpj Vaccines
Volume2
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

Tick-Borne Diseases
Tick-Borne Encephalitis Viruses
Tick-Borne Encephalitis
Vaccination
Vaccines
Flavivirus
Viruses
Ascitic Fluid
Ticks
Infection
Neutralizing Antibodies
Viral Load
Serum
Immunity
Morbidity
Mortality

ASJC Scopus subject areas

  • Pharmacology
  • Infectious Diseases
  • Immunology
  • Pharmacology (medical)

Cite this

Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection. / McAuley, Alexander J.; Sawatsky, Bevan; Ksiazek, Thomas; Torres, Maricela; Korva, Miša; Lotrič-Furlan, Stanka; Avšič-Županc, Tatjana; Von Messling, Veronika; Holbrook, Michael R.; Freiberg, Alexander; Beasley, David; Bente, Dennis.

In: npj Vaccines, Vol. 2, No. 1, 9, 01.12.2017.

Research output: Contribution to journalArticle

McAuley, Alexander J. ; Sawatsky, Bevan ; Ksiazek, Thomas ; Torres, Maricela ; Korva, Miša ; Lotrič-Furlan, Stanka ; Avšič-Županc, Tatjana ; Von Messling, Veronika ; Holbrook, Michael R. ; Freiberg, Alexander ; Beasley, David ; Bente, Dennis. / Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection. In: npj Vaccines. 2017 ; Vol. 2, No. 1.
@article{947af521fd9a4628bebfbb0ac3319fb7,
title = "Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection",
abstract = "The tick-borne encephalitis complex contains a number of flaviviruses that share close genetic homology, and are responsible for significant human morbidity and mortality with widespread geographical range. Although many members of this complex have been recognised for decades, licenced human vaccines with broad availability are only available for tick-borne encephalitis virus. While tick-borne encephalitis virus vaccines have been demonstrated to induce significant protective immunity, as determined by virus-neutralisation titres, vaccine breakthrough (clinical infection following complete vaccination), has been described. The aim of this study was to confirm the cross-neutralisation of tick-borne flaviviruses using mouse immune ascitic fluids, and to determine the magnitude of cross-neutralising antibody titres in sera from donors following tick-borne encephalitis vaccination, infection, and vaccine breakthrough. The results demonstrate that there is significant cross-neutralisation of representative members of the tick-borne encephalitis complex following vaccination and/or infection, and that the magnitude of immune responses varies based upon the exposure type. Donor sera successfully neutralised most of the viruses tested, with 85{\%} of vaccinees neutralising Kyasanur forest disease virus and 73{\%} of vaccinees neutralising Alkhumra virus. By contrast, only 63{\%} of vaccinees neutralised Powassan virus, with none of these neutralisation titres exceeding 1:60. Taken together, the data suggest that tick-borne encephalitis virus vaccination may protect against most of the members of the tick-borne encephalitis complex including Kyasanur forest disease virus and Alkhumra virus, but that the neutralisation of Powassan virus following tick-borne encephalitis vaccination is minimal.",
author = "McAuley, {Alexander J.} and Bevan Sawatsky and Thomas Ksiazek and Maricela Torres and Miša Korva and Stanka Lotrič-Furlan and Tatjana Avšič-Županc and {Von Messling}, Veronika and Holbrook, {Michael R.} and Alexander Freiberg and David Beasley and Dennis Bente",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41541-017-0009-5",
language = "English (US)",
volume = "2",
journal = "npj Vaccines",
issn = "2059-0105",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection

AU - McAuley, Alexander J.

AU - Sawatsky, Bevan

AU - Ksiazek, Thomas

AU - Torres, Maricela

AU - Korva, Miša

AU - Lotrič-Furlan, Stanka

AU - Avšič-Županc, Tatjana

AU - Von Messling, Veronika

AU - Holbrook, Michael R.

AU - Freiberg, Alexander

AU - Beasley, David

AU - Bente, Dennis

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The tick-borne encephalitis complex contains a number of flaviviruses that share close genetic homology, and are responsible for significant human morbidity and mortality with widespread geographical range. Although many members of this complex have been recognised for decades, licenced human vaccines with broad availability are only available for tick-borne encephalitis virus. While tick-borne encephalitis virus vaccines have been demonstrated to induce significant protective immunity, as determined by virus-neutralisation titres, vaccine breakthrough (clinical infection following complete vaccination), has been described. The aim of this study was to confirm the cross-neutralisation of tick-borne flaviviruses using mouse immune ascitic fluids, and to determine the magnitude of cross-neutralising antibody titres in sera from donors following tick-borne encephalitis vaccination, infection, and vaccine breakthrough. The results demonstrate that there is significant cross-neutralisation of representative members of the tick-borne encephalitis complex following vaccination and/or infection, and that the magnitude of immune responses varies based upon the exposure type. Donor sera successfully neutralised most of the viruses tested, with 85% of vaccinees neutralising Kyasanur forest disease virus and 73% of vaccinees neutralising Alkhumra virus. By contrast, only 63% of vaccinees neutralised Powassan virus, with none of these neutralisation titres exceeding 1:60. Taken together, the data suggest that tick-borne encephalitis virus vaccination may protect against most of the members of the tick-borne encephalitis complex including Kyasanur forest disease virus and Alkhumra virus, but that the neutralisation of Powassan virus following tick-borne encephalitis vaccination is minimal.

AB - The tick-borne encephalitis complex contains a number of flaviviruses that share close genetic homology, and are responsible for significant human morbidity and mortality with widespread geographical range. Although many members of this complex have been recognised for decades, licenced human vaccines with broad availability are only available for tick-borne encephalitis virus. While tick-borne encephalitis virus vaccines have been demonstrated to induce significant protective immunity, as determined by virus-neutralisation titres, vaccine breakthrough (clinical infection following complete vaccination), has been described. The aim of this study was to confirm the cross-neutralisation of tick-borne flaviviruses using mouse immune ascitic fluids, and to determine the magnitude of cross-neutralising antibody titres in sera from donors following tick-borne encephalitis vaccination, infection, and vaccine breakthrough. The results demonstrate that there is significant cross-neutralisation of representative members of the tick-borne encephalitis complex following vaccination and/or infection, and that the magnitude of immune responses varies based upon the exposure type. Donor sera successfully neutralised most of the viruses tested, with 85% of vaccinees neutralising Kyasanur forest disease virus and 73% of vaccinees neutralising Alkhumra virus. By contrast, only 63% of vaccinees neutralised Powassan virus, with none of these neutralisation titres exceeding 1:60. Taken together, the data suggest that tick-borne encephalitis virus vaccination may protect against most of the members of the tick-borne encephalitis complex including Kyasanur forest disease virus and Alkhumra virus, but that the neutralisation of Powassan virus following tick-borne encephalitis vaccination is minimal.

UR - http://www.scopus.com/inward/record.url?scp=85041545400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041545400&partnerID=8YFLogxK

U2 - 10.1038/s41541-017-0009-5

DO - 10.1038/s41541-017-0009-5

M3 - Article

AN - SCOPUS:85041545400

VL - 2

JO - npj Vaccines

JF - npj Vaccines

SN - 2059-0105

IS - 1

M1 - 9

ER -